Comparison between automated and user-interactive non-targeted screening tools: isotopic profile deconvoluted chromatogram (IPDC) algorithm and HaloSeeker 1.0

Author(s):  
S. Fakouri Baygi ◽  
S. Hutinet ◽  
R. Cariou ◽  
S. Fernando ◽  
P. K. Hopke ◽  
...  
NIR news ◽  
2012 ◽  
Vol 23 (5) ◽  
pp. 9-11 ◽  
Author(s):  
Jeffrey C. Moore ◽  
Arindam Ganguly ◽  
Jackie Smeller ◽  
Lucy Botros ◽  
Magdi Mossoba ◽  
...  

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 22-22
Author(s):  
Christos Mikropoulos ◽  
Elena Castro ◽  
Elizabeth Bancroft ◽  
Elizabeth Page ◽  
Natalie Taylor ◽  
...  

22 Background: Prostate cancer (PC) screening is controversial and a better assessment of individualized PC risk is needed. Several single nucleotide polymorphisms (SNPs) conferring a cumulative risk of PC have been identified. We have explored the potential role of genetic markers for targeted screening in a population with increased risk of PC due to family history (FH). Methods: PROFILE was developed as a pilot study to determine the feasibility of targeted PC screening using prostatic biopsy (PB) and its association with specific genetic profiles in men with FH. We also evaluated the role of PSA and Diffusion Weighted MRI (DW-MRI) as screening tools. One hundred sixteen men age 40 to 69 with FH of PC were enrolled between October 2009 and December 2012. Cumulative SNP risk scores were calculated by summing 59 risk alleles for each locus using the weighted effect (log-additive model). DW-MRI was performed in 50 patients. Participants were asked to undergo a 10 core PB regardless of baseline PSA. Results: Median age 53 (40 to 69) and median PSA was 1.15. One hundred and two men accepted to undergo a PB as primary PC screening. Twenty-three tumours were found (22.5% of biopsies) as well as seven men diagnosed with atypical small acinar proliferation (ASAP) (6.8%) and eight men with high-grade prostatic intraepithelial neoplasia (HG-PIN) (7.8%). In total 37.1% received an abnormal result. Out of the diagnosed PC 41% were intermediate or high risk and requiring treatment, which compares with 24% in general population screening. The predictive performance of DW-MRI, PSA, genetic model and genetic model plus PSA measured by AUC were: 0.85, 0.73, 0.57 and 0.74, respectively. The genetic model performed best in men with a normal PSA of <3(AUC 0.63). Analyses of a 78 SNP profile from the recent COGS results are underway. Conclusions: Ourresults indicate that PB is acceptable for PC screening in men with FH of PC. The significant AUC for DW-MRI would warrant a larger study. The incidence of ASAP is higher in this group than the general population.The SNP risk score was more predictive in men with PSA less than three where PB would not normally be undertaken, therefore an expanded study to investigate the role of genetic profiling in directing PB in PC screening is indicated.


2014 ◽  
Vol 71 (6) ◽  
pp. 366-373 ◽  
Author(s):  
Beate Wickop ◽  
Claudia Langebrake

Patienten ab einem Alter von 65 Jahren sind die bedeutendste Zielgruppe der Pharmakotherapie. Die im Alter häufig auftretende Multimorbidität bedingt oft eine Polymedikation. Eine leitliniengerechte Therapie aller Erkrankungen ist problematisch und selten in Studien an älteren Patienten geprüft. Zudem sind im Alter auftretende pharmakokinetische und pharmakodynamische Veränderungen zu beachten. Diese bedingen, dass bestimmte Medikamente für ältere Patienten potentiell inadäquat sind, weil sie ein hohes Risiko für unerwünschte Arzneimittelwirkungen bergen. Zur Identifikation von potentiell inadäquater Medikation wurden mehrere Negativlisten und Screening-Tools entwickelt. Im Artikel werden die START/STOPP-Kriterien, die PRISCUS-Liste, die Österreichische PIM-Liste sowie die FORTA-Einteilung näher erläutert. Der Einsatz dieser Tools kann die Qualität der medikamentösen Therapie im Alter verbessern. Zudem empfiehlt sich ein regelmäßiger Medikationsreview. Die Bestimmung der im Alter meist eingeschränkten Nierenfunktion und eine entsprechende Dosisanpassung der Medikation sowie die Wahl einer niedrigen Einstiegsdosis beim Ansetzen eines neuen Medikamentes bei älteren Patienten können ebenfalls einen Beitrag zur Arzneimitteltherapiesicherheit leisten.


2015 ◽  
Vol 40 (03) ◽  
Author(s):  
D Eglseer ◽  
AM Eisenberger ◽  
J Bergthaler ◽  
G Wirnsberger ◽  
RE Roller
Keyword(s):  

2004 ◽  
Vol 12 (2) ◽  
pp. 115-125
Author(s):  
Katrin Batereau ◽  
Martin Müller ◽  
Norbert Klaas ◽  
Baldur Barczewski

2017 ◽  
Vol 1 (3) ◽  
pp. 156-160
Author(s):  
Jacqueline Watchmaker ◽  
Sean Legler ◽  
Dianne De Leon ◽  
Vanessa Pascoe ◽  
Robert Stavert

Background: Although considered a tropical disease, strongyloidiasis may be encountered in non-endemic regions, primarily amongst immigrants and travelers from endemic areas.  Chronic strongyloides infection may be under-detected owing to its non-specific cutaneous presentation and the low sensitivity of commonly used screening tools. Methods: 18 consecutive patients with serologic evidence of strongyloides infestation who presented to a single urban, academic dermatology clinic between September 2013 and October 2016 were retrospectively included.  Patient age, sex, country of origin, strongyloides serology titer, absolute eosinophil count, presenting cutaneous manifestations, and patient reported subjective outcome of pruritus after treatment were obtained via chart review.  Results: Of the 18 patients, all had non-specific pruritic dermatoses, 36% had documented eosinophila and none were originally from the United States. A majority reported subjective improvement in their symptoms after treatment. Conclusion:  Strongyloides infection and serologic testing should be considered in patients living in non-endemic regions presenting with pruritic dermatoses and with a history of exposure to an endemic area.Key Points:Chronic strongyloidiasis can be encountered in non-endemic areas and clinical manifestations are variableEosinophilia was not a reliable indicator of chronic infection in this case series Dermatologists should consider serologic testing for strongyloidiasis in patients with a history of exposure and unexplained pruritus


Sign in / Sign up

Export Citation Format

Share Document